GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK70) » Definitions » EV-to-FCF

Conduit Pharmaceuticals (FRA:ZK70) EV-to-FCF : -1.21 (As of Apr. 01, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Conduit Pharmaceuticals's Enterprise Value is €10.90 Mil. Conduit Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-9.02 Mil. Therefore, Conduit Pharmaceuticals's EV-to-FCF for today is -1.21.

The historical rank and industry rank for Conduit Pharmaceuticals's EV-to-FCF or its related term are showing as below:

FRA:ZK70' s EV-to-FCF Range Over the Past 10 Years
Min: -0.75   Med: 0   Max: 0
Current: -0.75

FRA:ZK70's EV-to-FCF is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 3.34 vs FRA:ZK70: -0.75

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-01), Conduit Pharmaceuticals's stock price is €3.087. Conduit Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-17.916. Therefore, Conduit Pharmaceuticals's PE Ratio (TTM) for today is At Loss.


Conduit Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Conduit Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals EV-to-FCF Chart

Conduit Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EV-to-FCF
- - -43.05 -1.17

Conduit Pharmaceuticals Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.05 -33.32 -8.62 -1.30 -

Competitive Comparison of Conduit Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Conduit Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conduit Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's EV-to-FCF falls into.


;
;

Conduit Pharmaceuticals EV-to-FCF Calculation

Conduit Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10.901/-9.016
=-1.21

Conduit Pharmaceuticals's current Enterprise Value is €10.90 Mil.
Conduit Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Conduit Pharmaceuticals  (FRA:ZK70) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Conduit Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.087/-17.916
=At Loss

Conduit Pharmaceuticals's share price for today is €3.087.
Conduit Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.916.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Conduit Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Conduit Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4995 Murphy Canyon Road, Suite 300, San Diego, CA, USA, 92123
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines